Lead Product(s): Foralumab
Therapeutic Area: Immunology Product Name: TZLS-401
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Due to Foralumab’s ability to affect systemic immunity through the epithelial lining of the nose, respiratory tract and gut, it is the first antibody that can be dosed nasally or orally.